Literature DB >> 10473866

Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma.

A Sakamoto1, Y Oda, Y Iwamoto, M Tsuneyoshi.   

Abstract

Membrane type 1 matrix metalloproteinase (MT1-MMP) has been identified as an activator of the proenzyme of matrix metalloproteinase 2 (MMP-2: gelatinase A), and has also been shown to play a crucial role in tumor invasion by activating proMMP2 in both lung and gastric carcinoma. The tissue inhibitor of metalloproteinase 2 (TIMP-2) plus the MT1-MMP complex also plays an important role in the activation of proMMP-2. In this study, the expressions of MT1-MMP, MMP-2 and TIMP-2 were evaluated in 10 enchondromas, 34 conventional chondrosarcomas, 5 clear-cell chondrosarcomas, 7 mesenchymal chondrosarcomas and 8 dedifferentiated chondrosarcomas. The expressions were immunohistochemically visualized on paraffin sections and the levels of expression were assessed semiquantitatively. The extent of staining was assessed by the extent score in order to determine the overall level of expression. The extent scores of MT1-MMP, MMP-2 and TIMP-2 in grade 2 chondrosarcoma were significantly higher than those in either enchondroma or grade 1 chondrosarcoma (P < 0.05). In conventional chondrosarcoma, significant correlations were found between the extent scores of MT1-MMP and MMP-2 (P < 0.001), MT1-MMP and TIMP-2 (P < 0.01), and MMP-2 and TIMP-2 (P < 0.01). The undifferentiated small round tumor cells of mesenchymal chondrosarcoma showed lower positive rates and extent scores for MT1-MMP (2/7, 0.7 +/- 0.5) and MMP-2 (3/7, 0.7 +/- 0.4) than for cartilaginous components of mesenchymal chondrosarcoma [MT1-MMP (4/7, 1.3 +/- 0.5) and MMP-2 (7/7, 1.9 +/- 0.3)] or conventional chondrosarcoma. In dedifferentiated chondrosarcoma, the extent scores of MT1-MMP, MMP-2 and TIMP-2 in low-grade cartilaginous components were not significantly different from those in conventional chondrosarcoma; however, the high-grade anaplastic components showed high extent scores for MT1-MMP, MMP-2 and TIMP-2, compared with the low-grade cartilaginous components of dedifferentiated chondrosarcoma or conventional chondrosarcoma. According to our results, the expression of MT1-MMP as well as that of MMP-2 or TIMP-2 demonstrated a significant correlation with the tumor grade in human cartilaginous tumors. Furthermore, the expressions of MT1-MMP, MMP-2 and TIMP-2 were also found to play a crucial role in invasion in the high-grade components of dedifferentiated chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473866     DOI: 10.1007/s004320050314

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

2.  Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Authors:  Thomas Kalinski; Sabine Krueger; Antje-Friederike Pelz; Peter Wieacker; Roland Hartig; Martin Röpke; Regine Schneider-Stock; Frank Dombrowski; Albert Roessner
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

3.  Dedifferentiated chondrosarcoma of the middle finger arising from a solitary enchondroma: A case report.

Authors:  Hirotaka Yonezawa; Norio Yamamoto; Katsuhiro Hayashi; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Sei Morinaga; Yohei Asano; Shiro Saito; Yasunori Tome; Hiroko Ikeda; Takayuki Nojima; Hiroyuki Tsuchiya
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

4.  Expression of MT1-MMP during deciduous tooth resorption in odontoclasts.

Authors:  Busayarat Linsuwanont-Santiwong; Yuzo Takagi; Keiichi Ohya; Hitoyata Shimokawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study.

Authors:  Dominik Malcherczyk; Thomas J Heyse; Bilal F El-Zayat; Vanessa Kunzke; Roland Moll; Susanne Fuchs-Winkelmann; Jürgen R J Paletta
Journal:  BMC Musculoskelet Disord       Date:  2018-01-09       Impact factor: 2.362

6.  Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.

Authors:  Takashi Higuchi; Akihiko Takeuchi; Seiichi Munesue; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Inatani; Shingo Shimozaki; Takashi Kato; Yu Aoki; Kensaku Abe; Yuta Taniguchi; Hisaki Aiba; Hideki Murakami; Ai Harashima; Yasuhiko Yamamoto; Hiroyuki Tsuchiya
Journal:  Cancer Med       Date:  2018-03-23       Impact factor: 4.452

Review 7.  MMP14 in Sarcoma: A Regulator of Tumor Microenvironment Communication in Connective Tissues.

Authors:  Jordi Gonzalez-Molina; Silvia Gramolelli; Zehuan Liao; Joseph W Carlson; Päivi M Ojala; Kaisa Lehti
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

8.  Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute.

Authors:  Kazuya Yokota; Akio Sakamoto; Yoshihiro Matsumoto; Shuichi Matsuda; Katsumi Harimaya; Yoshinao Oda; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2012-12-10       Impact factor: 2.359

9.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.